Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
The list of cancers that may be susceptible to checkpoint inhibitors is quickly expanding, according to findings from clinical trials presented at the ASCO annual meeting.
-
In some patients with cancer that has spread to the brain, whole brain radiation following radiosurgery causes more severe cognitive decline and does not improve survival compared with radiosurgery alone, a new study has found.
-
The majority of Americans are not using sunscreen regularly to protect their skin from damage caused by the sun’s ultraviolet (UV) rays, according to a new survey.
-
Screening rates for breast, colorectal, and cervical cancer are lagging behind target rates set by the Healthy People 2020 program, according to a new study.
-
NCI has launched a new, dynamic, and easier-to-use version of NCI’s main websites, Cancer.gov and its counterpart in Spanish, Cancer.gov/espanol.
-
Tumor cells that are missing one copy of the tumor suppressor gene TP53 often harbor another genetic alteration that may make them susceptible to a targeted attack, according to a new study.
-
Findings from an early phase clinical trial may point to a biomarker that identifies patients with advanced non-small cell lung cancer most likely to respond to the immunotherapy drug pembrolizumab (Keytruda®).
-
A new study from NCI researchers is forecasting important trends in the types and molecular makeup of breast cancer cases through 2030, including a reduction in the proportion of cases that are considered to be difficult to treat.
-
A new study from NCI researchers finds that the HPV vaccine protects young women from infection with high-risk HPV types at the three primary anatomic sites where persistent HPV infections can cause cancer. The multi-site protection also was observed at lower levels in previously HPV-exposed women.
-
Yesterday, at the AACR annual meeting, Dr. Doug Lowy spoke directly to the research community about his goals as NCI Acting Director. Dr. Lowy said that he plans to continue many of the programs launched by his predecessor, Dr. Harold Varmus, and to sharpen the institute’s focus in several areas where he believes greater progress can offer significant dividends.